Active	Status	Sponsor type	Region	Phase	Filter
7 Active 8 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Campone, Mario
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
DF1001-001, NCT04143711: Study of DF1001 in Patients With Advanced Solid Tumors	Recruiting	1/2	378	Europe, US	DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy	Dragonfly Therapeutics	Solid Tumor, Adult	10/26	12/26
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer	Active, not recruiting	1	500	Europe, Japan, US, RoW	LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab	Eli Lilly and Company	Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer	06/20	12/27
NCT01481532: Open Label Clinical Trial of Intravenous Crotoxin Part 3	Not yet recruiting	1	24	Europe	Crotoxin, CB-24	Celtic Biotech Ltd, Institut de Cancérologie de l'Ouest	Cancer	08/25	12/25
POPCASE, NCT02890095: Persistent Organic Pollutants and Breast Cancers	Recruiting	N/A	800	Europe	Breast cancer surgery, plastic surgery	Institut Cancerologie de l'Ouest	Breast Cancer	03/25	03/35
CANTO, NCT01993498: Chronic Toxicities Related to Treatment in Patients With Localized Cancer	Recruiting	N/A	14750	Europe	blood sampling	UNICANCER	Breast Cancer Nos Metastatic Recurrent	03/34	03/34
EPICURE, NCT03958136: Clinico-biological Data Collection Study of Metastatic Breast Cancer	Recruiting	N/A	300	Europe	Metastasis biopsy, Biomarkers blood, urine and microbiota samples, Patient Reported Outcome (PRO)	Institut Cancerologie de l'Ouest, European Regional Development Fund, AstraZeneca, Novartis, Eli Lilly and Company	Breast Cancer	12/35	12/36